A Gain-switched 311-nm Titanium:Sapphire Laser Treatment in Palmoplantar Pustulosis
- Author:
Yong Woo OH
1
;
Dong Hee KIM
;
Byeong Hak SEO
;
Ho Seok SUH
;
Yu Sung CHOI
Author Information
1. Department of Dermatology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea
- Publication Type:Original Article
- From:Korean Journal of Dermatology
2020;58(9):601-607
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background:Palmoplantar pustulosis is a specific form of localized pustular psoriasis occurring on the palm and sole. Multiple therapeutic options, including topical and systemic agents as well as phototherapies, are available for palmoplantar pustulosis; however, treatment outcomes are not satisfactory in most cases. Recently, a gain-switched 311-nm Ti:Sapphire Laser was developed and showed good treatment response in vitiligo and atopic dermatitis.
Objective:To investigate the efficacy and safety of the 311-nm Ti:Sapphire Laser in the treatment of palmoplantar pustulosis.
Methods:A total of 24 patients with palmoplantar pustulosis were treated with a 311-nm Ti:Sapphire Laser twice a week for up to 32 sessions and had a 3-month follow-up visit. The treatment dose started at 300 mJ/cm 2 and was increased by 50 mJ/cm 2 at each subsequent session. The Palmoplantar Pustular Psoriasis Area and Severity Index score, 5-grade patient satisfaction score, and adverse events were evaluated.
Results:The mean Palmoplantar Pustular Psoriasis Area and Severity Index score decreased from 8.31±3.31 at baseline to 4.75±2.70 at 16 sessions, 3.26±2.18 at 32 sessions, and 4.05±2.19 at follow-up visit. In the subgroup analysis, non-smokers and emollients user groups showed better responses in Palmoplantar Pustular Psoriasis Area and Severity Index (p=0.033 and p=0.027, respectively). Adverse effects, including burning sensation and transient erythema, were limited and well-tolerated.
Conclusion:The 311-nm Ti:Sapphire Laser can be considered as a treatment option for palmoplantar pustulosis.Moreover, habitual risk factor modifications, such as smoking cessation and steady use of emollients, can impact treatment outcomes in patients with palmoplantar pustulosis.
